July 6 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 170.1 million euro ($185.1 million) in the first half of 2023, down 28% on the year, the company said on Thursday.
Consolidated sales revenue increased by an annual 7% to 920.4 million euro in January-June, with 93.8% of the total coming from sales abroad, Krka said in a statement on the group's preliminary operating results for the six-month period.
The first-half operating profit (EBIT) of the Krka group grew 70% on the year to 236.2 million euro, while the operating profit before depreciation and amortisation (EBITDA) went up 50% to 288.6 million euro.
The Krka group allocated 45.6 million euro to investments in the first six months of 2023, of which 36.5 million euro to the controlling company.
The group employed 11,653 workers at the end of June, with 45% of them employed by the subsidiaries of Krka d.d. abroad.
Eastern Europe generated the highest sales within the group - of 300.5 million euro, up 4% on the year, with product sales in Russia - Krka's largest individual market, rising also by 4%, to 179.8 million euro.
Sales in Central Europe rose 9% on the year to 212.9 million euro in January-June, followed by sales of 181.4 million euro in Western Europe, up by an annual 8%.
Sales in Southeast Europe grew 7% to 127.4 million euro in the period under review, whereas sales in Slovenia increased 15% to 56.6 million euro and sales in the Overseas Markets segment went up 16% to 37.6 million euro.
($ = 0.91909 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here